1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiationA trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
Seifter E, Bunn P, Cohen M, Makuch R, Dunnick N, Javadpour N, Bensimon H, Eddy J, Minna J, Ihde D. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. Journal Of Clinical Oncology 1986, 4: 1365-73. PMID: 2943877, DOI: 10.1200/jco.1986.4.9.1365.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials as TopicCyclophosphamideDiethylstilbestrolDoxorubicinDrug Therapy, CombinationHumansMaleMedroxyprogesteroneMedroxyprogesterone AcetateMiddle AgedNeoplasm MetastasisOrchiectomyPilot ProjectsProstatic NeoplasmsConceptsHormonal therapyCombination chemotherapyStable diseasePartial responseHormonal manipulationResponse rateInitial hormonal therapySubsequent hormonal manipulationUntreated metastatic carcinomaObjective response rateIntensive combination chemotherapyNormal testosterone levelsMetastatic prostate cancerEfficacy of chemotherapyProgression of diseaseTime of deathSimilar chemotherapyEndocrine treatmentUntreated patientsObjective responseOverall survivalMetastatic carcinomaModest efficacySerum testosteroneProstate cancerPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1985
The role of radiation therapy in the treatment of small cell lung cancer
Lichter A, Bunn P, Ihde D, Cohen M, Makuch R, Carney D, Johnston‐Early A, Minna J, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer 1985, 55: 2163-2175. PMID: 2983875, DOI: 10.1002/1097-0142(19850501)55:9+<2163::aid-cncr2820551420>3.0.co;2-y.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyCyclophosphamideDoxorubicinFollow-Up StudiesHumansLomustineLung NeoplasmsMethotrexateProcarbazineProspective StudiesRadiotherapyRadiotherapy DosageRandom AllocationTime FactorsVincristineWhole-Body IrradiationConceptsSmall cell lung cancerLimited-stage small cell lung cancerProphylactic cranial irradiationCell lung cancerCranial irradiationThoracic irradiationLung cancerExtensive-stage small-cell lung cancerComplete response statusLimited-stage diseaseOptimal treatment approachCombination of chemotherapyMinimum of toxicityLong-term survivalSystemic irradiationSystemic chemotherapyAggressive therapyPartial responseCNS failureResponse statusTreatment protocolOngoing protocolRadiation therapyTreatment approachesPatientsPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1983
Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy
Brower M, Ihde D, Johnston-Early A, Bunn P, Cohen M, Carney D, Makuch R, Matthews M, Radice P, Minna J. Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy. The American Journal Of Medicine 1983, 75: 993-1000. PMID: 6316784, DOI: 10.1016/0002-9343(83)90880-x.Peer-Reviewed Original ResearchConceptsHigh-intensity groupSmall cell bronchogenic carcinomaHigh-intensity therapyCell bronchogenic carcinomaInduction chemotherapyInduction courseInduction deathBronchogenic carcinomaDay 1Reversible congestive heart failureModerate-intensity therapyOverall median survivalCongestive heart failureSevere peripheral neuropathyModerate-intensity groupEvaluable patientsComplete remissionInduction therapyInfectious complicationsPartial remissionMedian survivalUntreated patientsComplete responseHeart failurePeripheral neuropathy
1982
The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes
Radice P, Matthews M, Ihde D, Gazdar A, Carney D, Bunn P, Cohen M, Fossieck B, Makuch R, Minna J. The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes. Cancer 1982, 50: 2894-2902. PMID: 6291745, DOI: 10.1002/1097-0142(19821215)50:12<2894::aid-cncr2820501232>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaSmall cell subtypeCell carcinomaResponse rateCombination chemotherapyClinical behaviorLong-term disease-free survivalCentral nervous system metastasesSmall cell carcinoma casesUntreated lung cancer patientsCell subtypesSmall cell lung cancerAggressive chemotherapy protocolsDistinct pathologic variantComplete response rateNervous system metastasesCell bronchogenic carcinomaDisease-free survivalIntensive combination chemotherapySmall cell cancerExtent of diseaseLarge cell carcinomaCell lung cancerLung cancer patientsLarge cell component
1980
Smoking abstinence and small cell lung cancer survival. An association.
Johnston-Early A, Cohen M, Minna J, Paxton L, Fossieck B, Ihde D, Bunn P, Matthews M, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980, 244: 2175-9. PMID: 6252357, DOI: 10.1001/jama.244.19.2175.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerSS patientsLung cancerCell lung cancer survivalThymosin fraction V.Lung cancer survivalDiscontinuation of smokingStart of treatmentContinuation of smokingSurvival benefitCigarette smokingPoor prognosisPrognostic implicationsCancer survivalSurvival differencesRadiation therapyBetter survivalPatientsSmokingBeneficial effectsS groupDiagnosisSurvivalTherapy
1979
Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241: 1813-5. PMID: 219267, DOI: 10.1001/jama.241.17.1813.Peer-Reviewed Original ResearchConceptsThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatmentCyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Cohen M, Ihde D, Bunn P, Fossieck B, Matthews M, Shackney S, Johnston-Early A, Makuch R, Minna J. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Journal Of The National Cancer Institute 1979, 63: 163-70. PMID: 221114.Peer-Reviewed Original ResearchConceptsSmall cell bronchogenic carcinomaResistant drug combinationsCell bronchogenic carcinomaCR rateCombination chemotherapyComplete responseBronchogenic carcinomaDrug combinationsExtensive disease patientsLimited disease patientsProtocol-eligible patientsHigh-dose cyclophosphamideBrain radiation therapyDisease-free survivalComplete respondersDrug regimensProlong survivalInitial treatmentRadiation therapyPatientsVP-16ChemotherapyCarcinomaSequential useMonths